Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. Show more
Location: 221 Crescent Street, Waltham, MA, 02453, United States | Website: https://www.viridiantherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.243B
52 Wk Range
$9.90 - $27.20
Previous Close
$15.23
Open
$15.17
Volume
396,632
Day Range
$14.98 - $15.94
Enterprise Value
716M
Cash
636.6M
Avg Qtr Burn
-69.94M
Insider Ownership
0.16%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VRDN-001 Details Thyroid Eye Disease | BLA Submission | |
VRDN-001 Details Thyroid Eye Disease | BLA Submission | |
VRDN-003 Details Thyroid Eye Disease | Phase 3 Data readout | |
VRDN-006 Details No known indication | Phase 1 Data readout | |
VRDN-008 Details No known indication | IND Submission |